August 9, 2022
Sonoran Biosciences Reports Publication of Analgesia Results for Postoperative Pain Program
TEMPE, Ariz., Aug 9, 2022 — Sonoran Biosciences (“Sonoran”), a preclinical-stage pharmaceutical company developing innovative hospital based products for the treatment of postoperative pain and surgical site infection, announced today the publication of analgesia results related to Sonoran’s product SBG004 (bupivacaine extended-release gel-forming solution) for treatment of postoperative pain. The publication in Pain Medicine describes a study evaluating the analgesic efficacy of SBG004 compared to saline, liposomal bupivacaine, bupivacaine collagen sponge, bupivacaine-meloxicam polyorthoester, and bupivacaine HCl in a porcine skin and muscle incision model widely used for evaluation of extended-release local anesthetics. The outcome of the porcine model is maximum tolerated force: a force applied at the incision from which the pig did not withdraw. Pharmacokinetic data following subcutaneous injection of SBG004 in rabbits are also reported.
Incisions receiving subcutaneous SBG004 had excellent outcomes throughout the study, with maximum tolerated forces greater than at pre-surgery baseline throughout the study, declining to near baseline by 168 hr postoperatively. In contrast, incisions in all other groups tolerated less force compared to pre-surgery baseline by 8 or 24 hr postoperatively. Pigs tolerated significantly greater force at incisions receiving subcutaneous SBG004 compared to saline at all time points through 96 hr and compared to liposomal bupivacaine at 24, 48, 72, and 96 hr. Systemic bupivacaine was detected for up to seven days post-dose in rabbits, indicating extended release.
The publication may be accessed at the following link: Extended Release of Bupivacaine from Temperature-responsive Hydrogels Provides Multi-day Analgesia for Postoperative Pain
About Sonoran Biosciences, Inc.
Sonoran Biosciences is a preclinical-stage pharmaceutical company leveraging its proprietary drug delivery technology to develop innovative hospital-based products for the treatment of postoperative pain and prevention of surgical site infections. Sonoran’s products are based on its proprietary SB Gel, an injectable carrier that forms a solid gel in the body, releases drugs over multiple days, and dissolves after the drugs are released. Sonoran’s lead products are SBG004, a long-acting formulation of bupivacaine, and SBG003, a fixed-dose combination of tobramycin and vancomycin for prevention of surgical site infection.